Addex Therapeutics Ltd
ADXN
$9.00
$0.19172.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -87.35% | -74.36% | -71.75% | -58.86% | -14.54% |
| Total Other Revenue | 1,550.98% | 44.68% | -31.48% | -75.00% | -71.02% |
| Total Revenue | -81.84% | -74.03% | -71.54% | -58.97% | -15.09% |
| Cost of Revenue | -35.39% | -27.11% | -70.53% | -76.64% | -88.48% |
| Gross Profit | -407.27% | -206.84% | 68.82% | 87.90% | 101.95% |
| SG&A Expenses | -27.82% | -11.95% | -23.95% | -39.57% | -46.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.04% | -16.62% | -46.08% | -59.30% | -74.08% |
| Operating Income | 3.95% | -24.38% | 35.36% | 59.38% | 80.80% |
| Income Before Tax | -96.64% | -99.11% | 6.21% | 52.68% | 79.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.64% | -99.11% | 6.21% | 52.68% | 79.67% |
| Earnings from Discontinued Operations | 267.42% | 246.54% | 262.05% | 291.24% | -329.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 174.52% | 164.32% | 146.34% | 133.19% | 30.00% |
| EBIT | 3.95% | -24.38% | 35.36% | 59.38% | 80.80% |
| EBITDA | 10.71% | -16.35% | 38.34% | 60.31% | 80.62% |
| EPS Basic | 162.83% | 148.12% | 128.28% | 113.80% | 61.52% |
| Normalized Basic EPS | -66.94% | -54.59% | 40.38% | 72.34% | 89.31% |
| EPS Diluted | 157.89% | 143.73% | 124.97% | 113.21% | 60.49% |
| Normalized Diluted EPS | -49.59% | -36.24% | 47.73% | 76.29% | 89.31% |
| Average Basic Shares Outstanding | 17.99% | 32.13% | 42.11% | 50.87% | 63.78% |
| Average Diluted Shares Outstanding | 38.89% | 55.58% | 68.13% | 80.12% | 63.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |